Epstein‐Barr Virus‐positive NK/T‐cell Malignancies in Poland: Distinctive Features, Therapeutic Strategies, and Survival Insights—The Real‐world Retrospective Report of the Polish Lymphoma Research Group
Asia-Pacific Journal of Clinical Oncology · 2026-08 · 22 (4) · 584-591
DOI: 10.1111/ajco.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 29.03.2026. Verfasst von Kateryna Filonenko und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Clinical Center, Gdańsk, Poland. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Aim
Extranodal NK/T‐cell lymphoma (ENKTCL) and aggressive NK‐cell leukemia (ANKL) are rare aggressive hematologic malignancies. Genetic differences and varying Epstein‐Barr virus (EBV) strains suggest potential disparities in disease characteristics in Europe compared to Asian countries. Our aim was to describe clinical characteristics and treatment approaches of these tumors in the solid Polish population. Materials and Methods A retrospective analysis of 23 patients diagnosed between 2018 and 2023 across six Polish centers was conducted (20 ENKTCL and three ANKL).
Results
Mean age was 50.1 years, with 73.9% male. Early stages and low‐risk dominated (75%). Common first‐line treatments included DeVIC (41%) and asparaginase‐based regimens (45%). Rituximab was used in three first‐line and two second‐line cases. Consolidation with autologous hematopoietic cell transplantation was performed in four and three cases, respectively. The 2‐year progression‐free survival (PFS) and overall survival (OS) were 57.8% and 75.2%, respectively. Early disease stage and response to the first‐line therapy were associated with higher PFS with hazard ratios (HRs) 3.5 (95% confidence interval [CI]: 1.6–8.97) and 1.84 (95% CI: 1.02–3.3), respectively. Hemophagocytic lymphohistiocytosis (HLH) was found in 21.7% of patients and was the strongest predictor of poor OS with HR 10.79 (95% CI: 1.96‐59.5).
Conclusions
The demographic and clinical characteristics of the Polish patient population were similar to those reported in Asian populations. Approximately 45% of patients received asparaginase‐containing regimens. The efficacy of first‐line regimens seemed to be lower compared to those reported in the literature. The presence of HLH is the most critical factor predicting poor survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Clinical Center, Gdańsk, Poland.
- Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland.
- Medical University of Warsaw, Warsaw, Poland.
- Jagiellonian University Medical College, Kraków, Poland.
- Medical University of Silesia, Katowice, Poland.
- Franciszek Łukaszczyk Oncology Center, Bydgoszcz, Poland.
Zitieren
APA
Filonenko, K., Paszkiewicz-Kozik, E., Drozd-Sokolowska, J., Szymanski, M., Giza, A., Kopinska, A., Chmielowska, E., & Zaucha, J. M. (2026). Epstein‐Barr Virus‐positive NK/T‐cell Malignancies in Poland: Distinctive Features, Therapeutic Strategies, and Survival Insights—The Real‐world Retrospective Report of the Polish Lymphoma Research Group. Asia-Pacific Journal of Clinical Oncology, 22(4), 584-591. https://doi.org/10.1111/ajco.70102
Vancouver
Filonenko K, Paszkiewicz-Kozik E, Drozd-Sokolowska J, Szymanski M, Giza A, Kopinska A, et al. Epstein‐Barr Virus‐positive NK/T‐cell Malignancies in Poland: Distinctive Features, Therapeutic Strategies, and Survival Insights—The Real‐world Retrospective Report of the Polish Lymphoma Research Group. Asia-Pacific Journal of Clinical Oncology. 2026;22(4):584-591. doi:10.1111/ajco.70102
BibTeX
@article{Filonenko2026,
author = {Filonenko, Kateryna and Paszkiewicz-Kozik, Ewa and Drozd-Sokolowska, Joanna and Szymanski, Marcin and Giza, Agnieszka and Kopinska, Anna and Chmielowska, Ewa and Zaucha, Jan Maciej},
title = {Epstein‐Barr Virus‐positive NK/T‐cell Malignancies in Poland: Distinctive Features, Therapeutic Strategies, and Survival Insights—The Real‐world Retrospective Report of the Polish Lymphoma Research Group},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {4},
pages = {584--591},
doi = {10.1111/ajco.70102}
}
EUVIMED